Combined anti-VEGF and anti–CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes

The combination of anti-VEGF blockade (bevacizumab) with immune checkpoint anti–CTLA-4 blockade (ipilimumab) in a phase I study showed tumor endothelial activation and immune cell infiltration that were associated with favorable clinical outcomes in patients with metastatic melanoma. To identify pot...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Immunol Res
Glavni autori: Wu, Xinqi, Li, Jingjing, Connolly, Erin M., Liao, Xiaoyun, Ouyang, Jing, Giobbie-Hurder, Anita, Lawrence, Donald, McDermott, David, Murphy, George, Zhou, Jun, Piesche, Matthias, Dranoff, Glenn, Rodig, Scott, Shipp, Margaret, Hodi, F. Stephen
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5509159/
https://ncbi.nlm.nih.gov/pubmed/28473314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0385
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items